US panel backs limiting Sanofi antibiotic uses
Fri, 15 Dec 2006 10:54 PM EST
... SILVER SPRING, Maryland (Reuters) - The Sanofi-Aventis antibiotic Ketek is safe enough to stay on the market for treating pneumonia, but regulators should withdraw approval for bronchitis and sinusitis, a U.S. advisory panel said on Friday. ...
Related Topics
- Antibiotics
- Liver Panel
- Antibiotic Resistance
- Hydrocortisone, Neomycin, and Polymyxin Otic
- Antibiotic-associated diarrhea
- Electrolytes
- Polymyxin B, Bacitracin, and Neomycin
- Cefuroxime
- Cephalexin
- Viral Infections
- Sulfamethoxazole and Trimethoprim
- Streptomycin
- Cefazolin Sodium Injection
- Gemifloxacin mesylate
- Nonoxynol-9
- Cefprozil
- Ceftriaxone Sodium Injection
- Chlamydia
- Tuberculosis
- Cellulitis

Not Signed In -


